There is clinical promise in the currently used proteotoxic-stress-promoting strategies—HDAC orheat shock protein (HSP) 90 + UPS inhibitors—albeit with some toxicity concerns in non-cancer cells and tissues [65,66]. This evidence concerns the gene HDAC9 and cancer.